Impact of the pandemic on routine immunisations for vaccine-preventable diseases
Routine childhood immunisation programmes have been disrupted because of Covid-19 and their implementation should be prioritised.
By
COVID Cross-sector Impact Brief
Latest in
COVID Cross-sector Impact Brief
Long Covid-19: drug trial results to watch in 2022
At least four long Covid-19 drug trial readouts are expected in 2022 that could shape the future of the therapeutic…
By
Trial Activity Snapshot: Did Australia’s “zero-Covid” plan protect clinical trial activity?
In an exclusive, Clinical Trials Arena dives into Australia’s trial activity data to find out how the pandemic impacted the…
By
Moderna eyes combined Covid-19, flu booster by 2023
Moderna CEO Stéphane Bancel also said an Omicron-specific Covid-19 vaccine will enter clinical development in a matter of weeks.
By
HDT Bio dose first subjects in Phase I Covid-19 vaccine trial
The trial will enrol 90 subjects to assess the safety, tolerability, and immunogenicity of three dose levels of the vaccine.
Bod Australia to start long Covid-19 trial using medicinal cannabis in UK
The trial intends to enrol up to 30 subjects who are aged over 18 years with long Covid-19.
Novartis and Molecular Partners report positive antiviral trial data
Novartis confirmed plans to in-license ensovibep from Molecular Partners for nearly $163m.
SAHPRA grants approval to begin trial of PaxMedica’s long Covid-19 therapy
The trial will assess the tolerability, safety, efficacy and PK of two varying doses of suramin in adult LCS patients.